{"title":"IV期胃癌患者在接受多肽树突状细胞免疫治疗联合标准治疗后获得完全缓解","authors":"Amane Sasada, Megumi Takagi, Shigeki Tabata, Minako Abe, Hiroyuki Abe","doi":"10.1016/j.pmu.2015.03.004","DOIUrl":null,"url":null,"abstract":"<div><p><span><span><span>In this report, we describe a 62-year-old male patient with stage IV gastric cancer who was treated with chemotherapy and dendritic cell immunotherapy<span> targeting the cancer antigens<span> WT1, </span></span></span>MUC1<span><span>, Her-2, and survivin. He then received WT1 and MUC1 peptides in combination with adjuvants near the lymph nodes or the </span>mucosa of the cancer lesion. Subsequently, a remarkable decrease in the size of the </span></span>gastric lesion<span><span>, in the swelling of metastatic lymph nodes, and the disappearance of </span>ascites<span> were observed. After 1 year and 2 months of the initial diagnosis, the patient underwent a robot-assisted gastrectomy and was able to return to work. In conclusion, multi-peptide dendritic cell immunotherapy in combination with conventional therapies resulted in remarkable anti-cancer effects and improved the patient's </span></span></span>quality of life.</p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"4 ","pages":"Pages 70-72"},"PeriodicalIF":0.0000,"publicationDate":"2015-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2015.03.004","citationCount":"4","resultStr":"{\"title\":\"A patient with stage IV gastric cancer who acquired complete remission after undergoing multi-peptide dendritic cell immunotherapy in combination with standard therapies\",\"authors\":\"Amane Sasada, Megumi Takagi, Shigeki Tabata, Minako Abe, Hiroyuki Abe\",\"doi\":\"10.1016/j.pmu.2015.03.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span><span><span>In this report, we describe a 62-year-old male patient with stage IV gastric cancer who was treated with chemotherapy and dendritic cell immunotherapy<span> targeting the cancer antigens<span> WT1, </span></span></span>MUC1<span><span>, Her-2, and survivin. He then received WT1 and MUC1 peptides in combination with adjuvants near the lymph nodes or the </span>mucosa of the cancer lesion. Subsequently, a remarkable decrease in the size of the </span></span>gastric lesion<span><span>, in the swelling of metastatic lymph nodes, and the disappearance of </span>ascites<span> were observed. After 1 year and 2 months of the initial diagnosis, the patient underwent a robot-assisted gastrectomy and was able to return to work. In conclusion, multi-peptide dendritic cell immunotherapy in combination with conventional therapies resulted in remarkable anti-cancer effects and improved the patient's </span></span></span>quality of life.</p></div>\",\"PeriodicalId\":101009,\"journal\":{\"name\":\"Personalized Medicine Universe\",\"volume\":\"4 \",\"pages\":\"Pages 70-72\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.pmu.2015.03.004\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Personalized Medicine Universe\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2186495015000085\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized Medicine Universe","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2186495015000085","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A patient with stage IV gastric cancer who acquired complete remission after undergoing multi-peptide dendritic cell immunotherapy in combination with standard therapies
In this report, we describe a 62-year-old male patient with stage IV gastric cancer who was treated with chemotherapy and dendritic cell immunotherapy targeting the cancer antigens WT1, MUC1, Her-2, and survivin. He then received WT1 and MUC1 peptides in combination with adjuvants near the lymph nodes or the mucosa of the cancer lesion. Subsequently, a remarkable decrease in the size of the gastric lesion, in the swelling of metastatic lymph nodes, and the disappearance of ascites were observed. After 1 year and 2 months of the initial diagnosis, the patient underwent a robot-assisted gastrectomy and was able to return to work. In conclusion, multi-peptide dendritic cell immunotherapy in combination with conventional therapies resulted in remarkable anti-cancer effects and improved the patient's quality of life.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
